Liquid Biopsy Market Research Report: Information
by Biomarker Types (Circulating Tumor Cells (CTCs), Circulating Tumor DNA
(CTDNA), Extracellular Vesicles (EVS) and other Biomarker (Circulating RNA and
Proteins)), Application (Cancer Therapeutic Application, Reproductive Health
and Other Therapeutic Application), Sample (Blood Sample, Urine Sample and
other), End User (Hospitals and Laboratories, Academic and Research Centers and
other End Users) and Region (North America, Europe, Asia-Pacific and Middle
East & Africa) - Global Forecast to 2022
Market Insights:
Liquid biopsy overcomes these problems of tissue biopsy by using
biomarkers present in samples such as blood, urine etc. and thus is a
comparatively non-invasive technique. Liquid biopsy also provides greater
information about the sample which is real time. The real time data can be used
for monitoring and thereby determining the treatment for diseases such as
cancer. The greater sensitivity of tissue biopsy coupled with the development
of sophisticated detectors with extremely low detection rates have enabled the
early detection of diseases which is the holy grail of cancer.
Biopsy involves extracting a sample of tissue and testing it for the
presence of diseases especially cancer. Traditional tissue biopsy is a painful
technique and also has a high rate of false results. Moreover the technique is
costly, time consuming and not applicable for extracting samples such as those
close to vital organs such as heart.
Segmentation:
Global Liquid Biopsy market has been
segmented on the basis of biomarker type which comprises of circulating tumor
cells (Ctcs), circulating tumor DNA (Ctdna), extracellular vesicles (Evs) and
other biomarker. On the basis of application; market is segmented into cancer
therapeutic application, reproductive health, and other therapeutic
application. On the basis of sample; market is segmented into blood, urine and
others. On the basis of end-users; market is segmented into hospitals and
laboratories, academic and research centres and others.
Major Players
·
Guardant
Health, Inc.,
·
Trovagene,
Inc.,
·
RainDance
Technologies, Inc.,
·
Agena
Bioscience Inc. Inc.,
·
Admera Health,
·
Biocept, Inc.,
·
Circulogene
Theranostics,
·
Inivata Ltd.,
·
SAGA
Diagnostics AB,
·
Exosome
Diagnostics and others.
Drivers
The market
drivers for the liquid biopsy market are rising rates of cancer, growing
investment in research and development, collaborations between companies and
public organizations, rise in geriatric population, rising expenditure on
health etc. The factors which are inhibiting the growth of the market includes
the prohibitive costs associated with liquid biopsy and the differential
awareness and availability between developing and the developed world. However,
not all cancer patients benefit from early detection as some cancer types such
as brain cancer and prostate cancer may lie dormant for many years. Further
liquid biopsy is not all non-invasive as can be seen in case of using spinal
fluid as sample.
Also the
technique is not applicable to all types of cancer as some cancers such as
brain cancer and prostate cancer may lie dormant for many years, and thus are
either undetectable or detected very late which robs liquid biopsy of its
advantages. Further liquid biopsy is not all non-invasive as can be seen in
case of using spinal fluid as sample.
Regional
Analysis:
Depending on
geographic region, Liquid biopsy market is segmented
into four key regions: Americas, Europe, Asia Pacific, and Middle East &
Africa. Globally developed countries led by North America is the largest market
for Liquid biopsy. Europe is the second-largest market for liquid biopsy. The
developing regions market such as Asia pacific region and Middle East &
Africa however is rising much faster.
Key findings
- Circulating tumor cells (CTCs) segment
dominates both in terms of market share as well as revenues, contributing
approx. 55.48% of the revenue share of the liquid biopsy market.
- On the basis of the therapeutic application,
the segment for Cancer will reflect the highest growth potential, with
over 82.83% of the market share by revenues. However, the urine sample
segment is anticipated to witness noticeable growth.
- The market for liquid biopsy is dominated by
North America and Europe and this trend will continue. Asia-Pacific market
is the fastest growing market and is expected to grow at a CAGR of 29.7%
during forecasted period
Browse More
Healthcare Reports @
